Clinical trial results suggest potential new treatment for primary biliary cholangitis

An international clinical trial involving UC Davis Health suggests the investigational drug Elafibranor is a potential novel treatment for patients with the rare, autoimmune disease primary biliary cholangitis. Results from the clinical trial showed significant improvements in biomarkers of disease progression. Patients also reported positive outcomes.

Leave A Comment

Your email address will not be published. Required fields are marked *